SEC Form 4 · accession 0001209191-15-004727
PORTOLA PHARMACEUTICALS INC · PTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Lis
Officer — Chief Executive Officer · Director
Period of report
Jan 15, 2015
Accepted (ET)
Jan 16, 2015 · 6:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001269021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 15, 2015 | M | 6,524 | $4.10 | A | 6,524 | D | |
| Common StockF2,F1 | Jan 15, 2015 | S | 6,524 | $26.776 | D | 0 | D | |
| Common StockF1 | Jan 16, 2015 | M | 13,476 | $5.10 | A | 13,476 | D | |
| Common StockF3,F1 | Jan 16, 2015 | S | 12,601 | $27.006 | D | 875 | D | |
| Common StockF4,F1 | Jan 16, 2015 | S | 875 | $27.314 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.10 | Jan 15, 2015 | M | 6,524 | D | Dec 23, 2008 | Dec 23, 2018 | Common Stock | 6,524 | 0 | D |
| Stock Option (Right to Buy)F1 | $5.10 | Jan 16, 2015 | M | 13,476 | D | Feb 25, 2009 | Feb 25, 2019 | Common Stock | 13,476 | 6,131 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2014, as amended August 17, 2014.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.34, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3) and (4) to this Form 4.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.29 to $27.29, inclusive.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.30 to $27.34, inclusive.